|
| 舒血宁注射液对缺血性中风患者神经功能恢复及抗动脉粥样硬化作用机制的研究 |
| A Study on Neurological Function Recovery andt he Mechanisms of Anti - atherosclerotic Effects of Shuxuening Injection in Ischemic Stroke Patients |
| 投稿时间：2025-04-07 修订日期：2025-04-23 |
| DOI： |
| 中文关键词: 舒血宁 尤瑞克林 神经功能恢复 动脉粥样硬化 作用机制 |
| 英文关键词: Sulxuenin Injection,Urinary Kallidinogenase for Injection, recovery of neurological function anti-atherosclerosis mechanisms |
| 基金项目:江西省中医药管理局科技计划项目资助（项目合同编号：2021A294） |
|
| 摘要点击次数: 16 |
| 全文下载次数: 0 |
| 中文摘要: |
| 【摘要】 目的：探讨联合舒血宁注射液神经功能恢复及抗动脉粥样硬化作用机制的研究。方法：根据纳排因素筛选入住神经内科青年型患者且诊断缺血性中风患者。主要结局因变量为美国国立卫生研究院卒中量表（National Institutes of Health Stroke Scale:NIHSS）评分和以Crouse斑块积分为因变量，以药物为自变量，调整混杂因素如年龄、性别等。建立模型分析两组药物对神经功能恢复、抗动脉粥样硬化的作用机制和评估复发情况。
结果：共纳入91名患者，其中单药组尤瑞克林41名患者，联合用药组尤瑞克林与舒血宁50名患者。神经功能恢复疗效：治疗后Crouse斑块积分与NIHSS评分呈独立负相关，风险降低24%（P＜0.05），统计显著（P＜0.05）。抗动脉粥样硬化作用机制：两组药物主要通过降低甘油三酯（TG）、低密度脂蛋白（LDL-C）和载脂蛋白B（APOB），升高高密度脂蛋白（HDL-C）和载脂蛋白A1（APOA1）治疗抗动脉粥样硬化，且风险明显降低（P＜0.05）。累积生存风险曲线：联合组复发累计风险更低，复发时间更长，然而两组差异并无统计学意义（P＞0.05）。结论：两组药物治疗都有助于神经功能恢复以及抗动脉粥样硬化作用。其中联合用药组较单药组治疗效果更显著，且有明显差异。两组累计生存曲线图未显示差异。 |
| 英文摘要: |
| Abstract
Objective: To explore the mechanisms of the recovery of neurological function and the anti-atherosclerotic effects of combined Shuxuening Injection.
Methods: Young patients diagnosed with ischemic stroke and admitted to the Department of Neurology in the hospital were screened according to inclusion and exclusion criteria. The main outcome dependent variables were the National Institutes of Health Stroke Scale (NIHSS) score and the Crouse plaque score. Drugs were set as the independent variable, and confounding factors such as age and gender were adjusted. Models were established to analyze the mechanisms of the effects of the drugs in both groups on the recovery of neurological function and anti-atherosclerosis, and to evaluate the recurrence situation.Results:A total of 91 patients were enrolled, with 41 patients in the monotherapy group receiving only Urinary Kallidinogenase for Injection and 50 patients in the combination group receiving both Urinary Kallidinogenase for Injection and Shuxuenin Injection..Regarding the neurological function recovery effect, after treatment, a negative correlation was observed between the Crouse plaque score and the NIHSS score. Notably, the risk was decreased by 24% (P < 0.05), which was statistically significant. Anti-atherosclerosis mechanism: The two groups of drugs mainly reduced the levels of triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (ApoB), and increasing the levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1 (ApoA1).This led to a significantly decreased risk (P＜0.05) in the progression of atherosclerosis.Conclusion: Both groups of drug therapy can contribute to the recovery of nerve function and anti-atherosclerotic effect.Significantly, the therapeutic efficacy of the combination group was more remarkable compared to that of the monotherapy group, presenting a significant difference. Nevertheless, the cumulative survival curves of the two groups failed to disclose any disparities. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
